MacLane Taggart represents both private and public life sciences clients in a broad range of capital markets transactions and also advises clients on corporate governance, Securities Exchange Act reporting requirements and other general corporate matters. MacLane is based in New York and is a member of Goodwin’s Life Sciences Group and Capital Markets practice. MacLane joined Goodwin in 2024.
MacLane maintains an active pro bono practice, with past representations including representing asylum seekers, transgender individuals in name change proceedings and entrepreneurs attending small business legal clinics.
MacLane received his JD from the University of Virginia School of Law. While at UVA, MacLane served as the Editor-in-Chief of the Virginia Tax Review. MacLane also graduated cum laude from the University of Utah Eccles School of Business with a degree in Accounting and a minor in Leadership Studies.
Professional Experience
- Represented Centessa Pharmaceuticals plc (Nasdaq: CNTA) in $258.7 million follow-on offering of American Depositary Shares
- Represented TD Cowen as sales agent for Sera Prognostics, Inc.’s (Nasdaq: SERA) “at-the-market” offering
- Represented Vigil Neuroscience, Inc. (Nasdaq: VIGL) in a $40 million strategic investment by Sanofi in exchange for convertible preferred stock
- Represented BofA Securities, Inc., SVB Securities LLC and Piper Sandler & Co. as representatives to the underwriters in connection with $80 million initial public offering and Nasdaq listing by Turnstone Biologics Corp. (Nasdaq: TSBX)*
- Represented Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC as representatives of the underwriters in connection with $250 million offering by CureVac N.V. (Nasdaq: CVAC)*
- Represented Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters in connection with $66 million offering by Vor Biopharma Inc. (Nasdaq: VOR)*
- Represented SVB Securities LLC as underwriter in connection with $30 million offering by Athenex, Inc. (Nasdaq: ATNX) of common stock, pre-funded warrants and common warrants*
- Represented BofA Securities and Mizuho Securities USA LLC as representatives of the initial purchasers in connection with the issuance and sale by Herbalife Nutrition LTD. (NYSE: HLF) of $250 million aggregate principal amount of 4.25% Convertible Senior Notes due 2028*
- Represented Jefferies LLC as sales agent for Calyxt, Inc.’s (Nasdaq: CLXT) “at-the-market” offering*
- Represented Goldman Sachs & Co. LLC, Evercore Group L.L.C., Barclays Capital Inc., Stifel, Nicolaus & Company, Incorporated as representatives to the underwriters in connection with $203 million initial public offering and Nasdaq listing by Vor Biopharma Inc. (Nasdaq: VOR)*
- Represented Syneos Health, Inc. (Nasdaq: SYNH) in connection with series of bided block trades in connection with the offering by selling stockholders of the Company’s common stock*
- Represented Endeavor Group Holdings, Inc. (NYSE: EDR) in $21 billion merger between Ultimate Fighting Championship and World Wrestling Entertainment, Inc. (NYSE: WWE), including NYSE listing of TKO Group Holdings, Inc (NYSE: TKO)*
- Represented Citigroup Global Markets Inc. as representative of the underwriters in connection with the SEC-registered issuance and sale by Ball Corporation (NYSE: BALL) of $1 billion aggregate principal amount of 6.000% Senior Notes due 2029*
- Represented PJT Partners LP as dealer manager and solicitation agent in the exchange by WeWork Companies LLC and WW Co-Obligor Inc., each subsidiaries of WeWork Inc. (NYSE: WE), of $507 million aggregate principal amount of their 7.875% Senior Notes due 2025 and $541 million aggregate principal amount of their 5.00% Senior Notes due 2025, Series II, in exchange for: $525 million aggregate principal amount of 15.00% (7.00% Cash/8.00% PIK) First Lien Senior Secured PIK Notes due 2027, Series I; $687 million aggregate principal amount of 11.00% (5.00% Cash/6.00% PIK) Second Lien Senior Secured PIC Notes due 2027; $23 million aggregate principal amount of 12.00% Third Lien Senior Secured PIC Notes due 2027; and approximately 1.1 billion shares of WE Class A common stock*
- Represented Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and U.S. Bancorp Investments, Inc. as representatives of the initial purchasers in connection with the issuance and sale by Berkshire Hathaway Energy Company of $1 billion aggregate principal amount of 4.600% Senior Notes due 2053*
- Represented BofA Securities, Inc., Barclays Capital Inc., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, BMO Capital Markets Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Citizens Capital Markets, Inc., SMBC Nikko Securities America, Inc. and TD Securities (USA) LLC as sales agents in connection with the “at-the-market” equity offering by B&G Foods, Inc. (NYSE: BGS)*
- Represented Jefferies LLC, Morgan Stanley & Co. LLC, BofA Securities, Inc. and Piper Sandler & Co. as representatives to the underwriters in connection with $466 million initial public offering and Nasdaq listing by Portillo’s Inc. (Nasdaq: PTLO)*
- Represented Oatly Group AB (Nasdaq: OTLY) in connection with $1.6 billion initial public offering of American Depositary Shares by the company and selling shareholders and Nasdaq listing*
- Represented Riskfied Ltd. (NYSE: RSKD) in connection with $396 million initial public offering by the company and a selling shareholder and NYSE listing*
Prior to joining Goodwin, MacLane was an associate in the Capital Markets group at Latham & Watkins LLP in New York.
*Denotes experience prior to joining Goodwin.
Credentials
Education
JD2019
University of Virginia
(Editor-in-Chief, Virginia Tax Review)
BAAccounting2016
University of Utah
(cum laude)
Admissions
Bars
- New York